Amylin Pharmaceuticals News
Most Popular Amylin Pharmaceuticals Story
FDA nod fuels Bydureon vs. Victoza bout
Amylin Pharmaceuticals' ($AMLN) projected blockbuster Bydureon has won FDA approval, adding muscle to the San Diego-based drug company's counterpunch against rival Novo Nordisk ($NVO) in the big Read more...
Latest Headlines
- January 30, 2012
- June 9, 2011
- July 14, 2010
- April 12, 2010
- February 16, 2010
- January 28, 2010
- January 13, 2010
- November 2, 2009
- August 25, 2009
- May 28, 2009
- May 22, 2009
- May 18, 2009
- May 6, 2009
- May 5, 2009
- April 28, 2009
- April 23, 2009
- April 21, 2009
- April 20, 2009
- April 16, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
